

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

10/649,378

Filing Date

August 25, 2003

First Named Inventor

Alan M. Fogelman

Group Art Unit

1614

Examiner Name

Unassigned

Total Number of Pages in This Submission

Attorney Docket Number

407T-911270US

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
☐ Fee Attached
☐ Amendment / Response
☐ After Final
☐ Affidavits/declaration(s)
☐ Extension of Time Request
☐ Express Abandonment Request
☒ Information Disclosure Statement
☐ Certified Copy of Priority Document(s)
☐ Response to Missing Parts/ Incomplete Application
☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
☐ Drawing(s)
☐ Licensing-related Papers
☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
☐ Petition to Convert to a Provisional Application
☐ Power of Attorney, Revocation Change of Correspondence Address
☐ Terminal Disclaimer
☐ Small Entity Statement
☐ Request for Refund

- ☐ After Allowance Communication to Group
☐ Appeal Communication to Board of Appeals and Interferences
☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
☐ Proprietary Information
☐ Status Letter
☒ Additional Enclosure(s) (please identify below):

USPTO Form 1449 Copy from Parent; receipt acknowledgment postcard

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENTFirm
or
Individual name

Tom Hunter, Reg. No. 38,498, Quine Intellectual Property Law Group, P.C.

Signature

Date

11 Nov 03

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Amelia Weintraub

Signature

Date

Nov. 11, 2003



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on Nov. 11, 2003

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By


Amelia Weintraub

Attorney Docket No. 407T-911270US
Client Ref. No. 2000-462-6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alan M. Fogelman, et al.

Application No.: 10/649,378

Filed: August 25, 2003

For: ORALLY ADMINISTERED SMALL
PEPTIDES SYNERGIZE STATIN
ACTIVITY

Examiner: Unassigned

Art Unit: 1614

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO-1449 form are being called to the attention of the Examiner to make of record references cited in parent application USSN 10/187,215 filed June 27, 2002. Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 10/187,215 filed June 27, 2002. are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner.

It is respectfully requested that the cited information on the attached 1449 form(s) be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Tom Hunter', with a long horizontal flourish extending to the right.

Tom Hunter, J.D., Ph.D.
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031


Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/187,215 10/649,378
Filing Date	June 27, 2002 August 26, 2003
First Named Inventor	Alan M. Fogelman
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	407T-011220US 407T-911270US
Date Submitted	February 5, 2003 Nov. 11, 2003



U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	01	3,767,040		Tushaus	10-23-1973	
	02	4,155,913		Hellerbach et al.	05-22-1979	
	03	4,643,988		Segrest et al.	02-17-1987	
	04	5,721,138		Lawn	02-24-1998	
	05	5,733,549		Yamada et al.	03-31-1998	
	06	5,814,467		Curtiss et al.	09-29-1998	
	07	5,854,238		Kempen	12-29-1998	
	08	6,037,323		Dasseux et al.	03-14-2000	
	09	6,086,918		Stern et al.	07-11-2000	

Examiner Initials		Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	10	WO	97/36927	A1	Boffelli et al.	10-09-1997		
	11	WO	99/47566	A1	The UAB Research Foundation	09-23-1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	12	ANANTHARAMAIAH (1986) "Synthetic Peptide Analogs of Apolipoproteins." <i>Methods in Enzymology</i> 128:627-647	
	13	ANANTHARAMAIAH and GARBER (1996) "Chromatographic Methods for Quantitation of Apolipoprotein A-I." <i>Meth. Enzymol.</i> 263: 267-282	
	14	ANANTHARAMAIAH et al. (1985) "Studies of Synthetic Peptide of the Amphipathic Helix." <i>The Journal of Biological Chemistry</i> 260:10248-10255	
	15	ANANTHARAMAIAH et al. (1990) "Use of Synthetic Peptide Analogues to Localize Lecithin: Cholesterol Acyltransferase Activating Domain in Apolipoprotein A-I." <i>Arteriosclerosis</i> 10:95-105	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/187,213 10/649,378
		Filing Date	June 27, 2002 August 26, 2003
		First Named Inventor	Alan M. Fogelman
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	4077-911220US 4077-911270US
		Date Submitted	February 5, 2003 11/11/03
16	ANANTHARAMAIAH et al. (1993) "An Atlas of the Amphipathic Helical Domains of Human Exchangeable Plasma Apolipoproteins." Chapter. 6:109-142 In: <i>The Amphipathic Helix</i> (Epanand, R. M., ed), CRC Press, Boca Raton, FL		
17	ARMSTRONG et al. (1993) D amino acid levels in human physiological fluids, <i>Chirality</i> , 5: 375-378		
18	BADIMON et al. (1990) "Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-fed Rabbit." <i>J. Clinical Investigation</i> 85:1234-1241		
19	BAUER et al. (1982) "SMS 201-995: A Very Potent and Selective Octapeptide Analogue of Somatostatin with Prolonged Action" <i>Life Sciences</i> 31:1133-1140.		
20	BOFFELLI et al. (1997) "Reconstitution and Further Characterization of the Cholesterol Transport Activity of the Small-Intestinal Brush Border Membrane" <i>Biochemistry</i> 36:10784-10792.		
21	BOFFELLI et al. (1997) "The uptake of cholesterol at the small-intestinal brush border membrane is inhibited by apolipoproteins." <i>FEBS Letters</i> , 411: 7-11		
22	BORHANI et al. (1999) "Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation." <i>Proc. Natl. Acad. Sci. USA</i> . 94:12291-12296		
23	BROUILLETTE and ANANTHARAMAIAH (1995) "Structural models of human apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1256: 103-129		
24	BROUILLETTE et al. (2001) "Structural Models of Human Apolipoprotein A-I: A Critical Analysis and Review" <i>Biochimica et Biophysica Acta</i> 557:53:1-44.		
25	Canadian Pharmacists Association, Starlix General Monograph. http://cpa.infinetcomm.com/content/hcp/tools/cps_cnp_updates/starlix.cfm		
26	CHUNG et al. (1985) "Studies of Synthetic Peptide Analogs of the Amphipathic Helix." <i>J. Biol. Chem.</i> 60(18): 10256-10262		
27	DATTA et al. (2001) "Effects of Increasing Hydrophobicity on the Physical-Chemical and Biological Properties of a Class A Amphipathic Helical Peptide." <i>J Lipid Research</i> 42:1096-1104.		
28	DAVIDSON et al. (1994) "The Influence of Apolipoprotein Structure on the Efflux of Cellular Free Cholesterol to High Density Lipoprotein." <i>J. Biol. Chem.</i> 269(37): 22975-22982		
29	DIEDERICH et al. (2001) "Apolipoprotein AI and HDL ₃ Inhibit Spreading of Primary Human Monocytes through a Mechanism that Involves Cholesterol Depletion and Regulation of CD42." <i>Atherosclerosis</i> 159:313-324.		
30	DOOLEY et al. (1994) "An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library" <i>Science</i> 2019-2022.		
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, with or without citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/167,215 10/649,378
Filing Date	June 27, 2002 August 25, 2003
First Named Inventor	Alan M. Fog Iman
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	407T-911220US 407T-911270US
Date Submitted	November 11, 2003

31	DUNLOP and NEIDLE (1997) "The Orgion and Turnover of D-Serine in Brain." <i>Biochemical and Biophysical Research Communication</i> 235:26-30	
32	EHARA et al. (2001) "Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes." <i>Circulation</i> 103:1955-1960	
33	EPAND et al. (1987) "Studies Synthetic Peptide Analog of the Amphipathic Helix" <i>J. Biol. Chem.</i> 262(19): 9389-9396	
34	FIELD et al. (2001) "Gene expression of sterol regulatory element-binding proteins in hamster small intestine." <i>Journal of Lipid Research</i> 42:1-9	
35	FIELDING and FIELDING (1995) "Molecular physiology of reverse cholesterol transport." <i>J. Lipid Res.</i> 36: 211-228	
36	FIELDING et al. (1972) "A Protein of Lecithin: Cholesterol Acyltransferase." <i>Biochem. Biophys. Res. Comm.</i> 46(2):1493-1498	
37	FRICKER et al. (1995) "Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 274:826-832	
38	FUESSL et al. (1987) "Oral Absorption of the Somatostatin Analogue SMS 201-995: Theoretical and Practical Implications" <i>Clinical Science</i> 72: 255-257.	
39	GARBER et al. (1992) "Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties." <i>Arteriosclerosis and Thrombosis</i> , 12(8): 886-894	
40	GARBER et al. (1997) <i>Circulation</i> 96-I-490	
41	GARBER et al. (1999) "Protection against Atherosclerosis in Mice by a Synthetic Class A Amphipathic Peptide Analog of Apolipoprotein A-I." <i>Circulation</i> 100: 2838	
42	GARBER et al. (2001) "A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis." <i>Journal of Lipid Research</i> 42:-545-552	
43	GLOMSET (1968) "The Plasma lecithin: cholesterol acyltransferase reaction." <i>J. Lipid Res.</i> 9:155-167	
44	GONG et al. (1994) "Structural and functional properties of human and mouse apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1213:335-342	
45	GURFINKEL et al. (2002) "Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study" <i>Circulation</i> 105:2143-2147.	
46	HAMASE et al. (2001) "Determination of Free D-Proline and D-Leucine in the Brains of Mutant Mice Lacking D-Amino Acid Oxidase Activity" <i>Analytical Biochemistry</i> 298:253-258.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number	10/187,215 10/649,378
Filing Date	June 27, 2002 August 26, 2003
First Named Inventor	Alan M. F. gelman
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	4077-911220US 4077-911270US
Date Submitted	February 5, 2003 11/1/03

(Use as many sheets as necessary)



47	HARDY et al. (2001) "An Automated High-Performance Liquid Chromatography Procedure for the Quantitation of L- and D-Amino Acids by Means of Stepwise Precolumn Derivatization" <i>Analytical Biochemistry</i> 291:297-299.
48	HASHIMOTO et al. (2000) "Improvement of intestinal absorption of peptides: absorption of B1-Phe monoglucosylated insulin to rat intestinal brush-border membrane vesicles." <i>J. Pharmaceutics & Therapeutics</i> 50(2):197-204
49	HAUSER et al. (1998) "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine" <i>Biochemistry</i> 178423-17850.
50	HAYRY et al. "Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat." <i>FASEB J.</i> 9(13):1336-1344
51	HYKA et al. (2001) "Apolipoprotein A-I Inhibits the Production of Interleukin-1beta and Tumor Necrosis Factor-alpha by Blocking Contact-Mediated Activation of Monocytes by T Lymphocytes." <i>Blood</i> 97:2381-2389.
52	JOHNSON et al. (1991) "Cholesterol transport between cells and high-density lipoproteins." <i>Biochim. Biophys. Acta.</i> 1085: 273-298
53	JONAS (1991) "Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins." <i>Biochim. Biophys. Acta</i> 1084: 205-220
54	JONAS (2000) Lecithin cholesterol acyltransferase." <i>Biochim. Biophys. Acta</i> 1529: 245-256
55	JONES et al. (1992) "Computer Programs to Identify and Classify Amphipathic alpha Helical Domains" <i>Journal of Lipid Research</i> 33:287-296.
56	KIGASAWA et al. (1995) "Inhibition of corneal ulceration by tetrapeptidyl hydroxamic acid." <i>Jap. J. Ophthalmology</i> 39(1):35-42
57	KREIGER (1999) "Charting The Fate of the "Good Cholesterol": Identification and Characterization of the High-Density Lipoprotein Receptor Sr-Bi." <i>Ann Rev. Biochem.</i> 68: 523-558
58	KULLMAN et al. (1999) "Evaluation of the Enantiomeric Composition of Amino Acids in Tobacco" <i>Chirality</i> 11:669-673.
59	SENIOR (1999) "New options developed for needle-free drug delivery" <i>Lancet</i> Sept. 25, 1999
60	LEVI et al. (2000) "A retro-inverso miniantibody with anti-HIV activity." <i>Aids Res. & Human Retrovirus</i> 16(1):59-65.
61	LUNDIN et al. (1986) "Absorption of Intragastrically Administered DDAVP in Conscious Dogs" <i>Life Sciences</i> 38:703-709.
62	MAN et al. (1987) D-aspartate in human brain." <i>J Neurochem</i> 48:510-515

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if r f r nc considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031


Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/167,215 10/649,378
Filing Date	June 27, 2002 August 26, 2003
First Named Inventor	Alan M. Fogelman
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	407T-911220US 407T-911270US
Date Submitted	February 5, 2003 11/11/03



63	MERRIFIELD et al. (1995) "Retro and Retroenantio Analogs of Cecropin-Melittin Hybrids" <i>Proc Natl Acad Sci USA</i> 92: 3449-3453.
64	MISHRA et al. (1994) "Interaction of Synthetic Peptide Analogs of the Class A" <i>J. Biol. Chem.</i> 269: 7185-7191
65	MISHRA et al. (1995) "Effect of the Arrangement of Tandem Repeating Units of Class A Amphipathic alpha-Helices on Lipid Interaction." <i>J. Biol. Chem.</i> 270: 1602-1611
66	MISHRA et al. (1998) "Studies of Synthetic Peptides of Human Apolipoprotein A-I Containing Tandem Amphipathic alpha-Helices" <i>Biochemistry</i> 37: 10313-10324
67	MOR et al. (1992) Enter a new post-translational modification: D-amino acids in gene-encoded peptides, <i>TIBS</i> , 17: 481-485
68	NAGATA et al. (1994) "Distribution of free D-serine in vertebrate brains", <i>Brain Res.</i> , 634: 291-295.
69	NAGATA et al. (1995) "Free D-serine concentration in normal and Alzheimer human brain", <i>Brain Res. Bull.</i> , 38(2): 181-183
70	NAVAB et al. (2000) "Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1." <i>J. Lipid Res.</i> 41: 1481-1494
71	NAVAB et al. (2000) "Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3." <i>J. Lipid Res.</i> 41: 1495-1508
72	NAVAB et al. (2002) "Oral Administration of an Apo A-I Mimetic Peptide Synthesized from D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol" <i>Circulation</i> 105: 290-292.
73	NOMOTO et al. (1998) "Improved of intestinal absorbtion of peptide drugs by Glycosylation: Transport of Tetrapeptide by the Sodium Ion-Dependent D-Glucose Transporter." <i>J. Pharmaceutics Science</i> 87(3):326-332.
74	OHTANI et al. (1995) Age-related changes in D-aspartic acid of rat teeth, <i>Growth Develop. & Aging</i> , 59: 55-61
75	ORAM and YOKOYAMA (1996) "Apolipoprotein-mediated removal of cellular cholesterol and phospholipids." <i>J. Lipid Res.</i> 37: 2473-2491
76	OWENS et al. (1990) "Apolipoprotein A-I and its Amphipathic Helix Peptide Analogues Inhibit Human Immunodeficiency Virus-Induced Syncytium Formation" <i>J Clin Invest</i> 86: 1142-1150.
77	PAIGEN et al. (1990) "Atherosclerosis Susceptibility Differences among Progenitors of Recombinant Inbred Strains of Mice." <i>Arteriosclerosis</i> 10: 316-323
78	PALGUNACHARI et al. (1996) "Only the Two End Xelises of Eight Tandem Amphipathic Helical Domains of Human Apo A-I Have Significant Lipid Affinity." <i>Arteriosclerosis, Thrombosis, & Vascular Biology</i> 16: 328-338

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PATENT

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number	10/107,245 10/649,378
Filing Date	June 27, 2002 August 26, 2003
First Named Inventor	Alan M. F gelman
Group Art Unit	1614
Examiner Name	Unassign d
Attorney Docket Number	407T-911220US 407T-911270US
Date Submitted	February 5, 2003 2/11/03

(use as many sheets as necessary)

- | | |
|----|---|
| 79 | PANIZZUTTI et al. (2001) "A New Strategy to Decrease N-methyl-D-aspartate (NMDA) Receptor Coactivation: Inhibition of D-serine Synthesis by Converting Serine Racemase into an Eliminase" <i>PNAS</i> 98:5294-5299. |
| 80 | PAPPENHEIMER et al. (1994) "Intestinal Absorption and Excretion of Octapeptides Composed of D Amino Acids" <i>Proc Natl Acad Sci USA</i> 91: 1942-1945. |
| 81 | PAPPENHEIMER et al. (1997) "Absorption and Excretion of Undegradable Peptides: Roles of Lipid Solubility and Net Charge." <i>J. Pharmacology & Experimental Therapeutics</i> 280(1):292-300 |
| 82 | PATSZTY et al. (1994) "Apolipoprotein AI Transgene Corrects Apolipoprotein E Deficiency-induced Atherosclerosis in Mice." <i>J. Clinical Investigation</i> 94:899-903 |
| 83 | PENG et al. (2001) "Effects of L-glutamate, D-aspartate, and Monensin on Glycolytic and Oxidative Glucose Metabolism in Mouse Astrocyte Cultures: Further Evidence that Glutamate Uptake is Metabolically Driven by Oxidative Metabolism" <i>Neurochemistry International</i> 38:437-443. |
| 84 | PHARMALICENSING (27 Jan. 2001) Esperion Builds a Novel Peptides Program (2 pages) |
| 85 | PHARMALICENSING (28 Jan. 2001) Multiple Peptide Systems Forms Joint Venture With Elan |
| 86 | PHARMALICENSING (28 Jan. 2001) Unigene to Receive Patent for Delivery of Peptide Pharmaceuticals (2 pages) |
| 87 | PHILIPS et al. (1993) "Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events." <i>Circulation</i> 88: 2762-2770 |
| 88 | PILONE (2000) D-amino acid oxidase: new findings. <i>CMLS, Cell. Mol. Life Sci.</i> , 57: 1732-1747 |
| 89 | PLUMP et al. (1994) "Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses stherosclerosis in the apolipoprotein E-deficient mouse." <i>Proc. Natl. Acad. Sci. USA</i> 91:9607-9611 |
| 90 | PURDUE NEWS (October 2000) 'Microspheres' Offer Promise for Oral Drug Delivery (3 pages) |
| 91 | PURDUE NEWS (September 12, 1997) New Oral Insulin Delivery System Shows Promise (3 pages) |
| 92 | REUBSAET et al. (1999) "Qualitative and quantitative aspects of the degradation of several tripeptides derived from the antitumour peptide antagonist [Arg ⁶ , D-Trp ^{7,9} , MePhe ⁸] substance P[6-11]." <i>J. Pharmaceut. & Biomed Analysis</i> 19(3-4):277-284 |
| 93 | RUBIN et al. (1991) "Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI." <i>Nature</i> 353:265-267 |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT


Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number	10/187,215 10/649,378
Filing Date	June 27, 2002 August 26, 2003
First Named Inventor	Alan M. F g lman
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	407T-9112200S 407T-911270US
Date Submitted	6/27/02 5/11/03

(use as many sheets as necessary)



94	SEGREST et al. (1974) "A Molecular Theory of Lipid-Protein Interaction in the Plasma Lipoproteins." <i>FEBS Lett.</i> 38: 247-253	
95	SEGREST et al. (1990) "Amphipathic Helix Motif: Classes and Properties." <i>Proteins: Structure, Function and Genetics</i> 8: 103-117	
96	SEGREST et al. (1992) "The Amphipathic Helix in the Exchangeable Apolipoproteins: A Review of Secondary Structure and Function" <i>J Lipid Research</i> 33:141-166.	
97	SEGREST et al. (1994) "The Amphipathic alpha Helix: A Multifunctional Structural Motif in Plasma Apolipoproteins." <i>Adv. Prot. Chem.</i> 45: 303-369	
98	SEGREST et al. (2000) "Structure and function of apolipoprotein A-I and high-density lipoprotein." <i>Current Opin. Lipidol.</i> 11:105-115	
99	SHAH et al. (1998) "Effect of Recombinant Apolipoprotein A-I _{Milano} on Aortic Atherosclerosis in Apolipoprotein E-Deficient Mice." <i>Circulation</i> 97:780-785.	
100	SINGH et al. (2000) "Innate Defences Against Viraemia" <i>Rev Med Virol</i> 10:395-403.	
101	SPRECHER et al. (1993) "The Low HDL Cholesterol/ High Triglyceride Trait." <i>Arterioscler. Thromb.</i> 13: 495-504	
102	SRINIVAS et al. (1990) "Antiviral Effects of Apolipoprotein A-I and Its Synthetic Amphipathic Peptide Analogs" <i>Virology</i> 176:48-57.	
103	Starlix MC—Amino Acid Fact Sheet. http://www.starlix.com/media_center/content/pages/amino.htm .	
104	SU AND AMIDON (1995) Investigation into the intestinal metabolism of [D-Ala] peptide T amide: implication for oral drug delivery, <i>Biochim et Biophys.</i> , 1245: 62-68	
105	THE WALL STREET JOURNAL (Jan 13, 2000) "Emisphere technologies develops oral Heparin"	
106	TSAI et al. (1998) D-serine added to antipsychotics for the treatment of schizophrenia. <i>Biol. Psychiatry</i> , 44: 1081-1089	
107	TSAO et al. (2001) "Hibernation-induction Peptide and Cell Death: [D-Ala ² , D-Leu ⁵]enkephalin Blocks Bax-related Apoptotic Processes" <i>European Journal of Pharmacology</i> 428:149-151.	
108	TSIMIKAS et al. (2001) "Measuring Circulating Oxidized Low-Density Lipoprotein to Evaluate Coronary Risk." <i>Circulation</i> 103:1930-1932	
109	VAN LENTEN et al. (2001) <i>Circulation</i> 103:2283-2288.	
110	VENKATACHALAPATHI et al. (1993) "Effect of End Group Blockage on the Properties of a Class A Amphipathic Helical Peptide." <i>Proteins: Structure, Function, and Genetics</i> 15:349-359.	
111	WILSON et al. (1988) "High Density Lipoprotein Cholesterol and mortality: The Framingham Heart Study." <i>Arteriosclerosis</i> 8: 737-741	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

A circular stamp from the Office of Intellectual Property (OIP). The text "OIP" is at the top, "STAT" is at the top right, "NOV 14 2003" is in the center, "PATENT & TRADEMARK OFFICE" is at the bottom, and "11" is at the bottom right.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Page 8 of 8